Social Media Ideas for Aldx

Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease - Slideshow

ADC Therapeutics SA (ADCT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference - Slideshow

Axsome rises on Auvelity prescription data

Ayvens (ALLDF) Analyst/Investor Day Transcript

Elixirr International plc (ELXXF) Q2 2026 Earnings Call Transcript

AGC and Neusignal Therapeutics Collaborate on the Development of Alzheimer's Disease Drug Candidate “NTX-083”

AGC Inc. (Headquarters: Tokyo; President: Yoshinori Hirai; hereinafter “AGC”) highlights its end-to-end support capabilities as a small-molecule pharmaceutical CDMO as demonstrated...

Odyssey Therapeutics, Inc. (ODTX) Discusses Additional Phase IIa Data for OD-001 in Ulcerative Colitis from UEG Week Pre...

Alsea, S.A.B. de C.V. (ALSSF) Q3 2026 Earnings Call Transcript

Allient Inc. (ALNT) Presents at Lake Street 10th Annual Best Ideas Growth Conference - Slideshow

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Earlier this month, we covered Definium Therapeutics’ second Phase 3 readout, this time pertaining to its first LSD (DT120) for generalised anxiety disorder (GAD) study. (See Smoot...

An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide

Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.

Align Technology, Inc. (ALGN) Presents at 2026 Global Healthcare Conference Transcript

Alkane Resources Ltd (ALK:CA) Presents at Mining Forum Americas 2026 - Slideshow

Axsome Therapeutics, Inc. (AXSM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder

This morning, LSD drug developer Definium Therapeutics shared positive topline data from its second Phase 3 study of its lead candidate, DT120, in generalised anxiety disorder (GAD...

IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026

IGC Pharma completes Phase 2 CALMA enrollment with 168 participants randomized, advancing toward database lock and expected Q4 2026 topline results.

Redox Limited (RDXLF) Shareholder/Analyst Call Transcript

Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

ADVX Expands Medical Business Consulting Services in Melbourne

Axsome Therapeutics, Inc. (AXSM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Avalyn Pharma Inc. (AVLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

UCB SA (UCBJY) Discusses EADV Data Highlights and Long-Term Impact of BIMZELX in Dermatology Transcript